Previous close | 2.4600 |
Open | 2.4900 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 2.3801 - 2.4900 |
52-week range | 2.1500 - 4.8000 |
Volume | |
Avg. volume | 35,340 |
Market cap | 172.086M |
Beta (5Y monthly) | 0.76 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4200 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.25 |
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC tumor models - JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 con
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024. Event:Guggenheim Securities Radiopharmaceuticals DayFormat:PresentationDate:May 13, 2024Time:11:30AM ETLocation:New York, NY Event:H.C. Wainwright 2ndAnnual BioConnect Investor ConferenceFormat:Fireside
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11th, 2024. Event:Jefferies Radiopharma Innovation SummitDate:April 11, 2024Time:12:40-1:10 PM ESTLocation:New York, NY Mr. Levy will also be available for 1x1 inv